GlassScriptPhysician profile
Amin Kamyar
NPI 1306879960
$3,672.92
in general payments reported to CMS, 2019-2025
21 companies · $854 in 2025
The $854 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2020: $27.11 · 2021: $354 · 2022: $679 · 2023: $517 · 2024: $596 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,966.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $459.44 | 2021-2025 | Lupkynis |
| Amgen INC. | $390.23 | 2019-2024 | Tavneos |
| Travere Therapeutics, INC. | $376.71 | 2024-2025 | Filspari |
| Mallinckrodt Enterprises LLC | $252.92 | 2019 | |
| Glaxosmithkline, LLC. | $240.56 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $234.14 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $229.20 | 2020-2025 | Acthar |
| Horizon Therapeutics Plc | $209.65 | 2019-2023 | Krystexxa |
| Genzyme Corporation | $182.98 | 2024-2025 | |
| Nuwellis, INC. | $136.88 | 2022 | |
| Chiesi USA, INC. | $130.73 | 2025 | Elfabrio |
| Novo Nordisk INC | $129.37 | 2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $120.44 | 2024 | |
| Ani Pharmaceuticals, INC. | $110.46 | 2023 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $103.35 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $100.00 | 2022 | |
| Abiomed | $82.21 | 2022 | |
| Fresenius USA Marketing, INC. | $80.22 | 2019-2024 | Velphoro |
| Rockwell Medical, INC. | $60.60 | 2019 | |
| Akebia Therapeutics INC | $29.75 | 2024 | Auryxia |
| Otsuka America Pharmaceutical, INC. | $13.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amin Kamyar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.